‘We Need Partners:’ KnowBe4 Stock Soars Upon Going Public
‘We are solely focused on making this a hugely powerful platform. We’re currently running away from the rest of the pack in terms of features,’ KnowBe4 Founder and CEO Stu Sjouwerman tells CRN. By Michael Novinson April 22, 2021, 04:06 PM EDT
KnowBe4 plans to rely exclusively on the channel as it uses some of the proceeds from its initial public offering to expand its footprint outside the United States.
The Clearwater, Fla.-based security awareness training vendor saw its stock surge $7.84 (49 percent) to $23.84 per share Thursday in its first day of trading on the Nasdaq Global Select Market, notching a valuation in excess of $3.5 billion. KnowBe4 had priced its initial public offering of 9.5 million shares at $16 each, putting the company on track to raise $152 million.
Latham Group, Inc. Announces Pricing of Initial Public Offering
April 22, 2021 19:53 ET | Source: Latham Pool Products Latham Pool Products Latham, New York, UNITED STATES
LATHAM, N.Y., April 22, 2021 (GLOBE NEWSWIRE) Latham Group, Inc. (“Latham” or the “Company”) today announced the pricing of its initial public offering of 20 million shares of its common stock at a price to the public of $19 per share. Latham is the largest designer, manufacturer and marketer of in-ground residential swimming pools in North America, Australia and New Zealand. With an operating history that spans over 60 years, the Company offers the industry’s broadest portfolio of pools and related products, including in-ground swimming pools, pool liners and pool covers.
Rain Therapeutics Announces Pricing of Initial Public Offering
April 22, 2021 19:03 ET | Source: Rain Therapeutics Inc Rain Therapeutics Inc Newark, California, UNITED STATES
NEWARK, Calif., April 22, 2021 (GLOBE NEWSWIRE) Rain Therapeutics Inc. (“Rain”), a clinical-stage company developing precision oncology therapeutics, today announced the pricing of its initial public offering of 7,352,941 shares of common stock at a public offering price of $17.00 per share. The gross proceeds to Rain from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Rain, are expected to be approximately $125.0 million. All of the shares are being offered by Rain. The shares are expected to begin trading on The Nasdaq Global Select Market on April 23, 2021 under the ticker symbol “RAIN.” In addition, Rain has granted the underwriters a 30-day option to purchase up to an addition
EMA Grants Accelerated Assessment Procedure for Nefecon for the Treatment of IgA Nephropathy
News provided by
Share this article
STOCKHOLM, April 23, 2021 /PRNewswire/
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ( Calliditas ) today announced that its lead product candidate Nefecon, a novel oral formulation targeting down regulation of IgA1 for the treatment of primary IgA Nephropathy (IgAN), has been granted accelerated assessment procedure by the European Medicine Agency s (EMA) Committee for Human Medicinal Products (CHMP).
Accelerated assessment, which may be granted when the CHMP concludes that the product is of major public health interest and major therapeutic innovation pursuant to Article 14 (9) of Regulation (EC) No 726/2004, reduces the timeframe for the EMA to review a marketing authorization application (MAA.) Typically, evaluating an MAA can take up to 210 procedure days, but accelerated assessment reduces the maximum timeframe for review